Reservation of Ordinary Shares. The Company shall ensure that there are at all times sufficient Ordinary Shares to provide for the issuance, free of any preemptive rights, out of its authorized but unissued Ordinary Shares or Ordinary Shares held in treasury, of the maximum aggregate number of Ordinary Shares underlying the ADSs that may be sold pursuant to the terms of this Agreement. The Company will use its commercially reasonable efforts to cause the ADSs to be listed for trading on the Trading Market and to maintain such listing.
Appears in 5 contracts
Samples: At the Market Offering Agreement (Canaan Inc.), At the Market Offering Agreement (BioLineRx Ltd.), At the Market Offering Agreement (ReneSola LTD)
Reservation of Ordinary Shares. The Company shall ensure that there are at all times sufficient Ordinary Shares to provide for the issuance, free of any preemptive rights, out of its authorized but unissued Ordinary Shares or Ordinary Shares held in treasury, of the maximum aggregate number of Ordinary Shares underlying represented by the ADSs that may be sold pursuant to the terms of this Agreement. The Company will use its commercially reasonable efforts to cause the ADSs to be listed for trading on the Trading Market and to maintain such listing.
Appears in 2 contracts
Samples: At the Market Offering Agreement (Immuron LTD), At the Market Offering Agreement (Immuron LTD)
Reservation of Ordinary Shares. The Company shall ensure that there are at all times sufficient Ordinary Shares to provide for the issuanceissuance of the ADSs, free of any preemptive rights, out of its authorized but unissued Ordinary Shares or Ordinary Shares held in treasuryshare capital under the capital band, of the maximum aggregate number of Ordinary Shares underlying represented by the ADSs that may be sold authorized for issuance by the Board pursuant to the terms of this Agreement. The Company will use its commercially reasonable efforts to cause the ADSs to be listed for trading on the Trading Market and to maintain such listing.
Appears in 1 contract
Samples: At the Market Offering Agreement (Addex Therapeutics Ltd.)
Reservation of Ordinary Shares. The Company shall ensure that there are at all times sufficient Ordinary Shares to provide for the issuance, free of any preemptive rights, out of its authorized but unissued Ordinary Shares or Ordinary Shares held in treasury, of the maximum aggregate number of Ordinary Shares underlying the ADSs that may be sold pursuant to the terms of this Agreement. The Company will use its commercially reasonable efforts to cause the ADSs Shares to be listed for trading on the Trading Market and to maintain such listing.
Appears in 1 contract
Samples: At the Market Offering Agreement (Enlivex Therapeutics Ltd.)
Reservation of Ordinary Shares. The Company shall ensure that there are at all times sufficient Ordinary Shares to provide for the issuance, free of any preemptive rights, out of its authorized but unissued Ordinary Shares or its Ordinary Shares held in treasury, of the maximum aggregate number of Ordinary Shares underlying the ADSs that may be sold pursuant to the terms of this Agreement. The Company will use its commercially reasonable efforts to cause the ADSs issuable pursuant to this Agreement to be listed for trading on the Trading Market and to maintain such listing.
Appears in 1 contract
Samples: At the Market Offering Agreement (Trinity Biotech PLC)
Reservation of Ordinary Shares. The Company shall ensure that there are at all times sufficient Ordinary Shares to provide for the issuance, free of any preemptive rights, out of its authorized but unissued Ordinary Shares or Ordinary Shares held in treasury, of the maximum aggregate number of Ordinary Shares underlying the ADSs that may be sold authorized for issuance by the Board pursuant to the terms of this Agreement. The Company will use its commercially reasonable efforts to cause the ADSs to be listed for trading on the Trading Market and to maintain such listing.
Appears in 1 contract
Samples: At the Market Offering Agreement (Stealth BioTherapeutics Corp)